Evidence map›Paper›PMID 38927568›Full record

ArticleBiomedicines2024

Ina Shehaj, Slavomir Krajnak, Katrin Almstedt, Yaman Degirmenci, Sophia Herzog, Antje Lebrecht, Valerie Catherine Linz, Roxana Schwab, Kathrin Stewen, Walburgis Brenner and 3 more

Abstract read
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ina ShehajDepartment of Obstetrics and Gynecology, University Medical Center, Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.
Slavomir KrajnakDepartment of Obstetrics and Gynecology, University Medical Center, Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.
Katrin AlmstedtDepartment of Obstetrics and Gynecology, University Medical Center, Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.
Yaman DegirmenciDepartment of Obstetrics and Gynecology, University Medical Center, Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.
Sophia HerzogDepartment of Obstetrics and Gynecology, University Medical Center, Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.
Antje LebrechtDepartment of Obstetrics and Gynecology, University Medical Center, Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.
Valerie Catherine LinzDepartment of Obstetrics and Gynecology, University Medical Center, Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.
Roxana SchwabDepartment of Obstetrics and Gynecology, University Medical Center, Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.ORCID 0000-0002-1489-0011
Kathrin StewenDepartment of Obstetrics and Gynecology, University Medical Center, Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.
Walburgis BrennerDepartment of Obstetrics and Gynecology, University Medical Center, Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.
Annette HasenburgDepartment of Obstetrics and Gynecology, University Medical Center, Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.
Marcus SchmidtDepartment of Obstetrics and Gynecology, University Medical Center, Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.ORCID 0000-0003-1365-2414
Anne-Sophie HeimesDepartment of Obstetrics and Gynecology, University Medical Center, Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) poses a challenge in establishing new treatment strategies and identifying new prognostic and predictive markers due to the extensive genetic heterogeneity of BC. Very few studies have investigated the impact of mRNA expression of these genes on the survival of BC patients.

methodsWe examined the impact of the mRNA expression of breast cancer gene type 1 (

resultsThe study was performed in a cohort of 461 patients with a median age of 62 years at initial diagnosis. The median follow-up time was 147 months. We could show that the lower expression of

conclusionsAccording to our observations,

Indexed as

BRCA1BRCA2breast cancermetagenemRNA expressionPALB2

Identifiers

PMID38927568
PMCPMC11202204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.